benign prostate hyperplasia. Enlarged prostate without lower urinary tract symptoms
Conditions
Interventions
Intervention 1: Intervention group: 3 capsules contain 250 mg of pomegranate peel extract, prepared in pharmaceutics laboratory of Mashhad pharmacy school, daily for 4 month. Intervention 2: Control g
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: age between 50-80 years Mild to moderate clinical diagnosis of BPH (patient has lower urinary (based on international prostate symptom score (IPSS)<18)
Exclusion criteria
Exclusion criteria: simultaneous use of BPH medications except tamsulosin use of supplements which existing in BPH such as saw palmetto, Quercetin vitamins having prostate or bladder cancer history of prostate surgery PSA>4mg/ml Post void residue (PVR)=200 ml history of allergy to pomegranate and its derivatives concomitant use of warfarin in both group and statins except rosuvastatin, tacrolimus, and cyclosporine in pomegranate group Patient dissatisfaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA serum level. Timepoint: at the beginning of the study and after 4m. Method of measurement: Enzyme Immuno Assay.;Prostate size. Timepoint: at the beginning of the study and after 4m. Method of measurement: sonography.;Post void volume. Timepoint: at the beginning of the study and after 4m. Method of measurement: sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reaction assessment e.g. low blood pressure. Timepoint: at the beginning of the study and monthly. Method of measurement: review and physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Elyasi
Mashhad University of Medical Sciences
Outcome results
None listed